December 28, 2018
CTI BioPharma prepares myelofibrosis patients for second phase testing of pacritinib
CTI BioPharma has enrolled 150 patients with myelofibrosis previously treated with ruxolitinibto be tested on pacritinib in the second phase, testing three dosing schedules over 24 weeks.